SCHEDULE 13G/A 0001062993-21-001369 0001450773 XXXXXXXX LIVE 1 Common Stock, $.0001 par value 12/20/2024 0001822791 Clene Inc. 185634102 6550 SOUTH MILLROCK DRIVE SUITE G50 SALT LAKE CITY UT 84121 Rule 13d-1(c) 4Life Research, LLC UT 314523.00 0.00 314523.00 0.00 314523.00 N 3.7 OO The amounts reported consist of 199,844 shares of common stock and 114,679 shares of common stock issuable upon conversion of a convertible promissory note held by 4Life Research, LLC, of which David Lisonbee is the majority beneficial owner and manager, and over which David Lisonbee may be deemed to have sole voting and dispositive power. The convertible promissory notes include a provision limiting the issuance of common shares upon conversion, to the extent such conversion, together with the exercise of any warrants, would require stockholder approval under the rules or regulations of the Nasdaq Stock Market. David Lisonbee UT 555328.00 0.00 555328.00 0.00 555328.00 N 6.5 IN The amounts reported consist of: (a) 199,844 shares of common stock and 114,679 shares of common stock issuable upon conversion of a convertible promissory note held by 4Life Research, LLC (reported on page 2 of this Schedule 13G), of which David Lisonbee is the majority beneficial owner and manager, and over which David Lisonbee may be deemed to have sole voting and dispositive power; (b) 27,131 shares of common stock held by Legato Investments, LLC, of which David Lisonbee is the majority beneficial owner and manager, and over which David Lisonbee may be deemed to have sole voting and dispositive power; (c) 114,679 shares of common stock issuable upon conversion of a convertible promissory note held by La Scala Investments, LLC, of which David Lisonbee is the majority beneficial owner and chairman, and over which David Lisonbee may be deemed to have sole voting and dispositive power; and (d) 36,495 shares of common stock and 62,500 shares of common stock underlying warrants held by David Lisonbee in his own name. The convertible promissory notes include a provision limiting the issuance of common shares upon conversion, to the extent such conversion, together with the exercise of any warrants, would require stockholder approval under the rules or regulations of the Nasdaq Stock Market. Clene Inc. 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121 4Life Research, LLC David Lisonbee 9850 South 300 West Sandy, UT 84070 4Life Research, LLC, Utah, United States David Lisonbee, Utah, United States Y 555,328 (The amounts reported consist of: (a) 199,844 shares of common stock and 114,679 shares of common stock issuable upon conversion of a convertible promissory note held by 4Life Research, LLC (reported on page 2 of this Schedule 13G), of which David Lisonbee is the majority beneficial owner and manager, and over which David Lisonbee may be deemed to have sole voting and dispositive power; (b) 27,131 shares of common stock held by Legato Investments, LLC, of which David Lisonbee is the majority beneficial owner and manager, and over which David Lisonbee may be deemed to have sole voting and dispositive power; (c) 114,679 shares of common stock issuable upon conversion of a convertible promissory note held by La Scala Investments, LLC, of which David Lisonbee is the majority beneficial owner and chairman, and over which David Lisonbee may be deemed to have sole voting and dispositive power; and (d) 36,495 shares of common stock and 62,500 shares of common stock underlying warrants held by David Lisonbee in his own name. The convertible promissory notes include a provision limiting the issuance of common shares upon conversion, to the extent such conversion, together with the exercise of any warrants, would require stockholder approval under the rules or regulations of the Nasdaq Stock Market.) 6.5% (As of January 21, 2025 (based on 8,248,719 shares of Common Stock outstanding as represented in the Issuer's Registration Statement on Form S-3 filed with the Securities and Exchange Commission on January 24, 2025.) 555,328 0 555,328 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. The undersigned hereby agree that the statement on Schedule 13G/A to which this Agreement is attached shall be filed by 4Life Research, LLC on its own behalf and on behalf of David Lisonbee. Date: February 14, 2025 4LIFE RESEARCH, LLC By: /s/ David Lisonbee, Manager DAVID LISONBEE By: /s/ David Lisonbee 4Life Research, LLC /s/ David Lisonbee 02/14/2025 David Lisonbee /s/ David Lisonbee 02/14/2025